- Home
- PIM vs ACHV Comparison
PIM vs ACHV Comparison
Compare PIM & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | ACHV |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 239.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIM | ACHV |
|---|---|---|
| Price | $3.32 | $5.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 57.5K | ★ 556.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.90 | $1.84 |
| 52 Week High | $3.28 | $5.78 |
Technical Indicators
Market Signals| Indicator | PIM | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 60.59 |
| Support Level | $3.32 | $4.30 |
| Resistance Level | $3.38 | $5.28 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 63.64 | 77.25 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.